Skip to Main Content

Paper Details

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Clin Cancer Res
23
2021
-468 genes, -MAPK pathway genes, -RAS, BRAF, BRAF V600, BRAF V600 wild-type melanoma, Cutaneous and Unknown Primary Melanomas, ERK, MAPK, NF1, NRAS, NRAS Q61, PD-1, Patients, RAS, RTK, melanoma, melanomas, patients, primary, programmed cell death protein 1, tumor
Author NameAffiliation
Walid K ChatilaMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Walid K ChatilaTri-Institutional Program in Computational Biology and Medicine, Weill Cornell Medical College
Arshi AroraMemorial Sloan Kettering Cancer Center
Francisco VegaMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Havish S KanthetiMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Suresh NairLehigh Valley Medical Center
Katherine S PanageasMemorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Nikolaus SchultzMarie-Josee & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center
  • 1 - 9

Datasets

Release 1.2